Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases – Kriya envisions treating people with NASH using a one-time intramuscular gene therapy enabling continuous expression of native FGF21 – – Kriya anticipates advancing its NASH gene therapy candidate...

Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases – Kriya's therapeutic pipeline addresses a broad range of diseases that collectively affect millions of patients worldwide—with a goal of delivering transformational clinical benefits with one-time...